FDA
-
-
-
-
-
-
-
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Liquidia Technologies (LQDA) PT Raised to $33 at Raymond James
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Liquidia Technologies (LQDA)
-
-
-
-
-
-
-
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Liquidia Technologies (LQDA)
-
-
-
-
-
-
-
Liquidia Technologies (LQDA) Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA inhalation powder for Patients Suffering with PAH and PH-ILD
-
-
-
-
-
-
-
Liquidia Technologies (LQDA) PT Lowered to $25 at BTIG
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

